with low cytotoxicity. The nanostructure achieved high loading capacity (81.25%) for the CDK4/6 inhibitor palbociclib and enabled efficient in vitro delivery, improving selectivity toward cancer cells. This platform demonstrates a scalable strategy for multifunctional, circular nanomedicine design.
Bastami et al. (Thu,) studied this question.